# TGD001 Treatment in Thrombotic Microangiopathies

> **NCT07459114** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **TargED Biopharmaceuticals B.V.** · enrollment: 70 (estimated)

## Conditions studied

- Thrombotic Microangiopathies
- ITP Immune-Mediated Thrombocytopenia

## Interventions

- **DRUG:** TGD001

## Key facts

- **NCT ID:** NCT07459114
- **Lead sponsor:** TargED Biopharmaceuticals B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-31
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-08-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07459114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07459114, "TGD001 Treatment in Thrombotic Microangiopathies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07459114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*